Publications by authors named "Y Irino"
Background: NY-ESO-1 and XAGE1 cancer/testis antigens elicit humoral and cellular immune responses in NSCLC patients. We aimed to predict clinical benefit with ICI monotherapy, using an automated immunoassay of NY-ESO-1/XAGE1 antibodies (Abs).
Methods: This study enrolled 99 NSCLC patients who received nivolumab after chemotherapy, including 21 patients harboring EGFR, ALK, or KRAS alterations.
Background: Patients with cancer, particularly those undergoing chemotherapy, are at risk from the low immunogenicity of Coronavirus Disease 19 (COVID-19) vaccines.
Methods: This prospective study assessed the seroconversion rate of COVID-19 vaccines among patients with cancer and hospital staff. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG (S-IgG) concentrations were evaluated before the first vaccination, and 1-3 and 4-6 months after the second vaccination.
Article Synopsis
- * Researchers analyzed data from 2,107 thoracic cancer patients between March 2020 and May 2021 and found that only 7 (0.3%) developed COVID-19, with most rRT-PCR tests revealing non-COVID-19 pneumonia or tumor fever instead.
- * The majority of patients who tested positive for COVID-19 also showed seroconversion, but the rate of false-negative cases was very low at 0.9%, suggesting that COVID-19 incidence in this group was minimal during the early pandemic
Immune checkpoint inhibitors (ICI) are key drugs in systemic therapy for advanced non-small-cell lung cancer (NSCLC) and have recently been incorporated into neoadjuvant and adjuvant settings for surgical resection. Currently, ICI combinations with cytotoxic agents are frequently used in clinical practice, although several ICI clinical trials have failed to produce long-term clinical benefits. Unfortunately, clinical benefit is moderate and limited considering physical and financial burden.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluates a fully automated plasma Aβ immunoassay that predicts brain Aβ status, which is relevant for diagnosing Alzheimer's disease (AD).
- The research included 197 participants in the discovery phase and 200 in the validation phase, with the Aβ42/Aβ40 ratio showing high accuracy in predicting amyloid PET results.
- This blood test is less invasive compared to traditional amyloid PET and cerebrospinal fluid methods, making it a more accessible option for clinicians and patients.